A new position paper published in The Lancet Regional Health – Europe calls for renewed and sustained investment in obesity prevention, warning that advances in pharmacological treatments must not divert attention from the root causes of the epidemic.
Endorsed by a pan-European team of over 700 researchers within the OBEClust initiative, the paper argues that while GLP-1 receptor agonists (such as Wegovy and Ozempic) represent a major breakthrough in obesity treatment, they cannot address the structural drivers underpinning rising obesity rates.
Obesity affects over one billion people globally and continues to increase across Europe, driven by factors including unhealthy food environments, urban design that discourages physical activity, socioeconomic inequality, and commercial determinants of health.
“Pharmacological treatments can improve health outcomes for individuals, but they have considerable disadvantages and do not remove the root causes of obesity,” says Dr. Jeroen Lakerveld from Amsterdam UMC, one of the paper’s lead authors. “Without structural change, the inflow of new patients will remain high. Prevention is essential for achieving sustainable and equitable health improvements at the population level.”
The paper outlines key policy priorities, including:
- Strengthening food system regulation
- Promoting active environments
- Addressing socioeconomic inequalities
- Integrating prevention and treatment strategies
It also highlights the economic risks of relying heavily on long-term pharmacotherapy without addressing underlying causes, warning of escalating costs for health systems.
As part of the OBEClust initiative, SHIFT2HEALTH contributes to this coordinated European effort, supporting research that addresses both behavioural and biological determinants of obesity.
The authors conclude that the emergence of new therapies should reinforce – not replace – the case for prevention.